What changed
Royalty Pharma posted Q3 FY26 Portfolio Receipts of $890M, up 9.3% YoY, with net income of $267M. Top-line growth was driven by Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by Promacta declines on U.S. generic competition and weaker Imbruvica. Management raised FY2026 Portfolio Receipts guidance to $3.5B–$3.55B from $3.4B–$3.5B.
Why it matters
Royalty Pharma posted Q3 FY26 Portfolio Receipts of $890M, up 9.3% YoY, with net income of $267M. Top-line growth was driven by Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by Promacta d